Evidence map›Paper›PMID 42189090›Full record

ArticleStatistics in medicine2026

A General Framework for Designing and Evaluating Active-Controlled Trials with Non-Inferiority Objectives.

Antonio Olivas-Martinez, Fei Gao, Holly Janes

Abstract read
In one paragraph

Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Antonio Olivas-MartinezDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-2779-0068
Fei GaoBioinformatics and Epidemiology Program Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-6797-5468
Holly JanesBioinformatics and Epidemiology Program Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.

Funding

SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
NIAID NIH HHS UM1 AI068635NIH HHS UM1AI068635
6 · The paper itself

Abstract

Active-controlled trials with non-inferiority objectives are often used when effective interventions are available, but new options may offer advantages or meet public health needs. In these trials, participants are randomized to an experimental intervention or an active control. The traditional non-inferiority criterion requires that the new intervention preserve a substantial proportion of the active control effect. A key challenge is the absence of a placebo arm, which necessitates reliance on historical data to estimate the active control effect and assumptions about how well this effect applies to the target population. Another challenge arises when the active control is highly effective, as the new intervention may still be valuable even if it does not meet the traditional criterion. This has motivated alternative criteria based on sufficient efficacy relative to a hypothetical placebo. In this work, we propose a general framework for designing and evaluating non-inferiority trials that integrates all existing analytical methods and accommodates both traditional and alternative success criteria. The framework enables the systematic comparison of methods in terms of type I error, power, and robustness to misspecification of the active control effect. We illustrate its applicability in the design of a future HIV prevention trial with a highly effective active control. In this application, our framework identifies methods that provide greater efficiency and robustness than commonly used approaches and demonstrates practical advantages of the alternative non-inferiority criterion. Overall, this framework offers a comprehensive toolkit for rigorous non-inferiority trial design, supporting method selection and the evaluation of new interventions.

Indexed as

Equivalence Trials as TopicRandomized Controlled Trials as TopicResearch DesignAnti-HIV AgentsHIV InfectionsHumansModels, StatisticalAnti-HIV Agentsactive‐controlled trialshistorical controlsinferred efficacynon‐inferioritypreservation of effectstudy design

Identifiers

PMID42189090
PMCPMC13527659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.